Comparison

Balsalazide sodium hydrate European Partner

€192.00
Excl. VAT
Item no. HY-B0667A-50mg
Manufacturer MedChem Express
CASRN 150399-21-6
Amount 50mg
Category
Type Inhibitors
Specific against other
Purity 99.61
Citations [1]Do EJ, et al. Suppression of colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway by balsalazide and VSL#3. J Gastroenterol Hepatol. 2016 Aug;31(8):1453-61.
[2]Kruis W, et al. Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. Gut, 2001. 49(6): p. 783-789.
Smiles O=C(O)C1=CC(/N=N/C2=CC=C(C(NCCC(O[Na])=O)=O)C=C2)=CC=C1O[Na].O.O
ECLASS 10.1 32160490
ECLASS 11.0 32160490
UNSPSC 12000000
Alias Balsalazide disodium dihydrate
Available
Product Description
Balsalazide sodium hydrate could suppress colitis-associated carcinogenesis through modulation of IL-6/STAT3 pathway.
StorageTemperature
4°C (Powder, sealed storage, away from moisture and light)
Shipping
Room Temperature
Manufacturers Applications
COVID-19-immunoregulation
Molecular Weight
437.31
Clinical Information
Launched
Solubility
DMSO : 125 mg/mL (ultrasonic)
Isoform
IL-1; IL-6; STAT3
Pathway
Immunology/Inflammation; JAK/STAT Signaling; Stem Cell/Wnt
Manufacturers Product type
Reference compound

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 50mg
Available: In stock
Listprice: €192.00
Price: €192.00
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close